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Abstract We applied cDNA selection methods to a genomic
clone (YAC 761B5) from chromosome 21 located in the so-called
‘Down critical region’ in 21q22.3. Starting from human fetal
heart and brain mRNAs we obtained and sequenced several
cDNA clones. One of these clones (Down region aspartic
protease (DRAP), named also BACE2 according to the gene
nomenclature) revealed a striking nucleotide and amino acid
sequence identity with several motifs present in members of the
aspartic protease family. In particular the amino acid sequences
comprising the two catalytic sites found in all mammalian
aspartic proteases are perfectly conserved. Interestingly, the
predicted protein shows a typical membrane spanning region;
this is at variance with most other known aspartic proteases,
which are soluble molecules. We present preliminary evidence, on
the basis of in vitro translation studies and cell transfection, that
this gene encodes a glycosylated protein which localizes mainly
intracellularly but to some extent also to the plasma membrane.
Furthermore DRAP/BACE2 shares a high homology with a
newly described L-secretase enzyme (BACE-1) which is a
transmembrane aspartic protease. The implications of this
finding for Down syndrome are discussed.
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1. Introduction
The endopeptidases dependent on aspartic residues for their
catalytic activity (EC 3.4.23) belong to three main families
which are those of the pepsin (A1), retropepsin (A2) and
that of the pararetroviruses such as the cauli£ower mosaic
virus (A3) [1]. The A1 family comprises several members,
among which the widely known cathepsin D, cathepsin E,
chymosin, gastricsin, pepsin A, pepsin F and renin are all
related by extensive sequence homology [1^3].
Similarities in three-dimensional (3D) structures [4^7] to-
gether with sequence homologies indicate that all aspartic
proteases are likely to resemble one another very closely. In
particular the re¢ned structures for fungal/vertebrate enzymes
are broadly similar with dimensions of ca 65U40U30 Aî ;
these proteases are bilobed molecules with the active-side cleft
located between the lobes and with each lobe contributing one
of the pair of aspartic acid residues responsible for the cata-
lytic activity [8,9]. Furthermore, the catalytic aspartic acid
residues occur within the motif Asp-Ser/Thr-Gly in both N-
and C-terminal lobes of the enzyme. This structural organiza-
tion is most likely derived from gene duplication events [3].
Recently a new member of the family has been described
which shows an unprecedented transmembrane spanning do-
main [10]. This protein cleaves the amyloid precursor protein
(APP) at the NH2 terminus of the amyloid L peptide AL to
release APPsL, a 100 kDa soluble NH2-terminal fragment,
leaving a 12 kDa COOH-terminal fragment (C99) bound to
the membrane [11]. The new protein was called BACE-1 for
L site APP-cleaving enzyme [10].
We present here the cDNA sequence of a gene sharing
several features with the members of the A1 family of aspartic
proteases and in particular with BACE-1. Interestingly the
gene encoding the new cDNA is located on the long arm of
chromosome 21 in the so called ‘Down critical region’ at
21q22.3 and was therefore dubbed DRAP for Down region
aspartic protease. We have also partially characterized the
protein product encoded by the cloned cDNA.
2. Materials and methods
2.1. Direct cDNA selection
Poly(A)+ mRNA was prepared from human fetal heart and brain
with the oligotex mRNA kit (Promega). 5 Wg of mRNA were reverse
transcribed into double strand cDNA, which was digested with MboI
and ligated to synthetic oligonucleotide linkers as previously described
[11].
The human chromosome 21-derived YAC 761B5 is a non-chimeric
clone that was obtained from the CEPH library. YAC DNA was
separated from the endogenous yeast chromosomes by preparative
pulsed ¢eld gel electrophoresis (PFGE) and puri¢ed [12]. The enrich-
ment for transcripts deriving from genes mapping to the YAC was
achieved essentially as described [11].
2.2. In vitro transcription and translation
Plasmid pSP64Tnew was derived from pSP64T [13] by linearization
with BglII and insertion of a synthetic polylinker carrying the recog-
nition sites for the restriction enzymes ApaI, XhoI, HpaI and NotI.
PSP64Tnew DNA was digested to completion with NotI, blunted with
Klenow enzyme and digested with ApaI prior to agarose gel puri¢ca-
tion. The cDNA clone containing the putative aspartic protease ORF
was digested with XbaI and the DNA was blunted with Klenow en-
zyme and digested with ApaI thus producing a 1710 bp DNA frag-
ment (containing the whole ORF) which was gel puri¢ed and ligated
to the pSP64Tnew vector. The plasmid DNA was then linearized by
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BamHI digestion and transcribed in vitro with SP6 RNA polymerase
in the presence of m7GpppG for 90 min at 40‡C as described [14]. The
RNA was extracted once with 1:1 phenol-chloroform, once with
chloroform and ¢nally once with dimethylether before being ethanol
precipitated with 0.3 M sodium acetate and resuspended in DEPC-
treated water in the presence of 1 unit/Wl of RNasin. In vitro trans-
lation was performed with wheat germ extracts (Promega) in the pres-
ence of 35S-labeled methionine according to the supplier’s protocol. 1^
2 Wg of transcribed RNA were used in a 25 Wl reaction that was
allowed to proceed for 1 h at 25‡C.
When indicated, 1 Wl of Canine Microsomal Membranes (Promega)
was included in the reaction. The samples were then analyzed by
SDS^PAGE on a 15% polyacrylamide gel followed by autoradiogra-
phy. Proteinase K treatment of translation reactions was performed at
a ¢nal concentration of 100 Wg/ml for 30 min on ice in the presence or
absence of 0.5% Triton X-100, immediately followed by protease in-
activation with 5 mM phenylmethylsulfonyl £uoride. Endo H treat-
ment was performed with the deglycosilation kit from Boehringer
Mannheim according to the manufacturer’s instructions; brie£y, 5 Wl
of the translation mixture were incubated at 95‡C for 3 min in the
presence of one volume of bu¡er 2, then 10 Wl of reaction bu¡er and
10 Wl of Endo H were added to the sample and incubated at 37‡C for
di¡erent times; control reactions contained no Endo H enzyme.
Translocation of polypeptides to the luminal side of the microsomes
was further con¢rmed by prevention of N-linked glycosylation
through competitive inhibition following the inclusion in the in vitro
translation reaction of the glycosylation acceptor tripeptide (acetyl)-
Asn-Tyr-Thr-(amide) [15]. As an independent assay for N-glycosyla-
tion, the L-glucosidase inhibitor N-methyl deoxynojirimycin (Hett-
kamp et al., 1984) was included in the in vitro translation reaction
at a ¢nal concentration of 3 mM. To analyze the translocated proteins
under alkaline conditions, a 10 Wl aliquot of the proteins translated in
the presence of microsomal membranes was incubated on ice with 490
Wl of 100 mM Na2CO3 (pH 11.5) for 30 min, pelleted by centrifuga-
tion at 100 000Ug for 30 min and rinsed with ice-cold PBS before
SDS^PAGE analysis.
The supernatant was also collected and its content precipitated with
10% TCA before electrophoresis.
2.3. Sequence analysis of DRAP-1/BACE2
Protein sequence alignments were initially performed with the pro-
gram Clustal W [16] (http://www.infobiogen.fr/docs/ClustalW/
clustalw.html), and then manually modi¢ed with the sequence editor
Seaview [17] (ftp://pbil.univ-lyon1.fr/pub/mol_phylogeny/seaview),
taking into consideration the alignment of the DRAP-1 sequence to
those of aspartic proteases of known structure obtained from the
SWISS-MODEL program. Secondary structure predictions were per-
formed using the programs Predator [18] (http://www.embl-heidel-
berg.de/cgi/predator_serv.pl) and PHDsec [19] (http://www.embl-hei-
delberg.de/predictprotein/predict protein.html). In order to evaluate
whether the DRAP-1 amino acid sequence could be compatible with
the conserved fold of the aspartic protease protein class, its fold was
predicted using three di¡erent recognition algorithms: 3D-PSSM [20]
(http://bonsai.lif.icnet.uk/fold¢tnew/index.html), Gon+predss [21]
(http://fold.doe-mbi.ucla.edu/Home) and TOPITS [22] (http://
www.embl-heidelberg.de/predict protein/predictprotein.html).
3. Results
3.1. Identi¢cation of DRAP/BACE2
Two YAC clones from chromosome 21 (761B5 and 773A5
clones from the CEPH library) which are adjacent in 21q22.3
and span approximately 1800 kb of genomic DNA were se-
lected for gene isolation. Human mRNAs from endocardium,
myocardium and total brain were used for cDNA selection
procedures and several clones were obtained, sequenced and
compared with database sequences using the BLASTN and
BLASTX programs. We present here the characterization of
a cDNA clone (761-2) from YAC 761B5 which shows high
homology with several human ESTs (98^100% identity) and
mouse EST W10530 (81.4%), respectively. Clone 761-2 was
found to reside on chromosome 21 at the expected location
in 21q22.3 by both FISH analysis and Southern blot analysis
with a human-mouse hybrid containing chromosome 21 as the
only human chromosome (data not shown). When clone 761-2
was used to probe ¢lters containing mRNA from several adult
and fetal human tissues, two bands of approximately 2.2 and
2.7 kb were detected in most of the tissues investigated (Fig.
1); the highest levels of expression were found in heart, pan-
creas, prostate and placenta. Lower expression was found in
other tissues including brain (Fig. 1), where spinal cord and
medulla exhibited the highest levels (not shown). The cDNA
corresponding to the 2.2 kb band was isolated (clone 2.2A)
and characterized. The nucleotide and deduced protein se-
quences of this clone are presented in Fig. 2. The sequence
shows the presence of an ORF of 518 amino acids based on
the ¢rst ATG at position 109 (the sequence around the ¢rst
ATG has a good homology to the Kozak consensus sequence)
£anked by a 5P UTR of 108 bp and a 3P UTR of 197 bp
respectively.
An initial similarity search against the SWISS-PROT pro-
tein database using the amino acid sequence encoded by clone
2.2A revealed a central core, corresponding to residues 82^
329, with up to 32.2% identity to members of the A1 family of
aspartyl endopeptidases (lowest BLAST E-value = 1e-26). Sig-
ni¢cantly, the amino acid residues comprising the two cata-
lytic sites found in all mammalian aspartic proteases (Asp-Ser/
Thr-Gly-Ser/Thr) are perfectly conserved in the cDNA clone,
at positions 110^113 and 303^306, respectively. Furthermore,
all the residues immediately adjacent to these sites are com-
Fig. 1. Northern analysis of cDNA clone 761-2: total RNA (25 Wg)
from several human tissues was separated in a denaturing formalde-
hyde gel, transferred to positively charged nylon membranes and
probed with random-primed labeled clone 761-2 DNA. Two hybrid-
izing bands of approximate molecular weight of 2.2 and 2.7 kb
were observed in most tissues analyzed (top panels). Normalization
of RNA content in the blots was achieved following hybridization
of the same ¢lters with a L-actin probe (bottom panels). The tissue’s
nomenclature is as follows: H: heart; Br: brain; Pl: placenta; Lu:
lung; Lv: liver; Sk: skeletal muscle; Kd: kidney; Pc: pancreas; Sp:
spleen; Th: thymus; Pr: prostate; Ts: testis; Ov: ovary; In: intes-
tine; Cl: Colon; PB: peripheral blood cells.
C
Fig. 2. Sequence of cDNA clone 2.2A: The 1881 bp sequence of the insert of clone 2.2A is shown. The ATG start codon lies at position 109
and is followed by a 518 residues ORF terminating with the stop codon TGA at position 1663. The two catalytic triads (DTG and DGS) are
boxed. Two potential N-glycosylation sites are circled. A putative transmembrane domain is underlined.
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patible with the PROSITE pattern de¢ned for the aspartic
protease class (accession number PS00141). Taken together,
these ¢ndings prompted us to give this novel gene the name
DRAP, the gene nomenclature has approved the symbol
BACE2 for this gene).
The presence of a signal peptide (residues 1 to 20) predict-
ing cleavage between Ala-20 and Ala-21 was indicated by
analysis using a speci¢c algorithm for the prediction of signal
peptide sequences (web site http://genome.cbs.dtu.dk); how-
ever no homology was observed between this peptide and
signal peptides of other aspartic proteases. This ¢nding is
not totally unexpected, as it is known that signal peptides in
general have a low level of primary sequence conservation.
Although most aspartic proteases have activation peptides
with a similar sequence and structural homology to one an-
other, we failed to observe any sequence of DRAP/BACE2
that could be reminiscent of such conserved sequences. Two
potential N-glycosylation sites at amino acid positions 170
and 366 were also noted in the coding region of clone 2.2A.
Further sequence analysis also predicted the presence of
hydrophobic domains suitable to serve as membrane spanning
regions: submission of the protein sequence to two di¡erent
membrane spanning prediction algorithms (TMPred [23].
(http://www.isrec.isb-sib.ch/software/TMPRED_form.html ;
moment transmembrane helix prediction at the UCLA-DOE
Fold-Recognition server [21]. (http://fold.doe-mbi.ucla.edu/
Home), yielded a number of domains among which the abso-
lute highest score was achieved by the segment enclosed be-
tween Ala at position 474 and Phe at position 494.
The latter 21 amino acid stretch is predicted to form a
transmembrane domain that would confer to the whole pro-
tein the orientation of a type 1a integral membrane protein
[11]. Such membrane topology is suggested by the presence of
several basic arginine residues located at the C-terminal side
of the putative transmembrane domain [24,25]. Thus, consid-
ering the location of this second hydrophobic domain (near
the C-terminus of the ORF), most of the protein would be
expected to translocate across the ER membrane following
translation of the putative aspartic protease-encoding
mRNA, leaving a C-terminal 24 amino acid untranslocated
stretch on the cytoplasmic side.
Furthermore once the sequence of BACE-1 (Fig. 3) became
available it was obvious that DRAP/BACE2 and BACE-1 are
much more similar to one another than to any other member
of the aspartic protease family; the two proteins are in fact
45% identical and 71% homologous. As indicated in Fig. 3,
the positions of the predicted signal peptide cleavage sites, of
the putative transmembrane regions, of one of the putative
glycosylation sites and of the lumenal cysteine residues are
conserved between the two proteins.
The prediction of such transmembrane domain in DRAP/
BACE2 was a rather unexpected ¢nding, as most aspartic
proteases described so far in vertebrates are known to be
secreted proteins. We therefore assessed whether sequences
with similar properties also existed in other vertebrate species.
To this end, we decided to clone the mouse homologue of
DRAP/BACE2 by screening a mouse skeletal muscle cDNA
library with EST W10530, which was previously shown to
bear a signi¢cant homology with DRAP/BACE2; a partial
cDNA covering the most 3P end of the sequence correspond-
ing to amino acid 264^518 of the human sequence was ob-
tained. Both at the nucleotide and amino acid level a remark-
able identity is present between the two sequences. In
Fig. 3. Alignment of the open reading frame predicted from the
cDNA sequence of the human DRAP/BACE2 clone to the sequence
of human BACE-1 protein (GenBank accession number AF190725).
Numbers indicate amino acid positions. Identical amino acids are
shaded in grey and homologous ones (GES scale) are outlined in
black. The boxes including DRAP-1 residues 107 to 118 and 300 to
311 indicate the amino acids corresponding to the canonical aspartic
protease PROSITE pattern (PROSITE accession number PS00141),
with the conserved signature sequences D T/S G T/S marked. Pre-
dicted signal peptide cleavage sites and transmembrane domains are
indicated by red arrows and boxed in cyan, respectively. Putative
N-linked glycosylation sites are marked with pale dots, lumenal cys-
teine residues are indicated by dark dots.
Fig. 4. SDS^PAGE analysis of in vitro translated DRAP/BACE2.
A: the DRAP/BACE2 coding region was cloned into the expression
vector pSP64Tnew as described in Section 2, the resulting construct
was transcribed in vitro and the puri¢ed RNA was translated in vi-
tro in the presence of [35S]methionine; the reaction products (5 Wl
per lane) were then analyzed on a 15% denaturing polyacrylamide
gel. In vitro translation reactions were performed in the presence
and absence of canine pancreatic microsomal membranes, and ali-
quots of the reactions were further treated with proteinase K and
Triton X-100 (as indicated in the diagram below the picture) under
the conditions described in Section 2. The two vertical lines on the
left side of the picture represent the position of the protein molecu-
lar weight marker bands corresponding to 46 and 66 kDa. B: In vi-
tro translated DRAP was treated with a solution of 100 mM so-
dium carbonate at pH 11.5 as described in Section 2 to disrupt the
microsomal membranes and the membrane-containing fraction was
harvested by centrifugation at 100 000Ug for 30 min. Aliquots from
the membrane fraction (lane 2) and the supernatant (lane 3) were
then analyzed by SDS^PAGE together with a sample of protein
that was not fractionated (lane 1). The two vertical lines on the left
side of the picture represent the position of the protein molecular
weight marker bands corresponding to 46 and 66 kDa.
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particular, the predicted transmembrane domain (spanning
amino acids 474^494 in the human sequence) is well conserved
in the mouse cDNA clone, since over a stretch of 21 amino
acids only two substitutions are present at positions 488 (Val-
Leu) and 494 (Phe-Leu), respectively (data not shown). The
C-terminal catalytic site (DSG) was also perfectly conserved
in the murine cDNA. Thus a gene encoding a putative trans-
membrane aspartic protease seems to exist also in the mouse.
3.2. In vitro synthesis of DRAP/BACE2
In order to assess whether the DRAP predicted transmem-
brane domains are functional, cDNA clone 2.2A was in vitro
transcribed and the RNA was translated with wheat germ
extracts; SDS^PAGE analysis of the in vitro translation prod-
ucts revealed a major polypeptide with the expected Mr of 56
kDa (Fig. 4A, lane 1). When canine pancreatic microsomal
membranes were included in the translation reaction, addi-
tional polypeptides of 58 and 60 kDa were observed, presum-
ably representing glycosylated molecules (Fig. 4A, lane 4).
The appearance of polypeptides migrating faster than the 56
kDa polypeptide was occasionally observed, and their nature
was not further investigated.
Proteinase K treatment of the translation products showed
that while the vast majority of the 56 kDa polypeptide syn-
thesized in the absence of microsomal membranes was suscep-
tible to proteolytic attack (Fig. 4A, lane 2), the 58 and 60 kDa
polypeptides synthesized in the presence of microsomes were
largely resistant, indicating that they had been translocated
into the microsomal vesicles (Fig. 4A, lane 5). A small amount
of the 56 kDa protein was also consistently observed after
proteinase K treatment (lane 5), and may represent either
translocated protein that has not yet been glycosylated, or a
small residue of the untranslocated 56 kDa band that escaped
degradation, or a mixture of both; we favor the former ex-
planation on the basis of the results obtained following so-
dium carbonate treatment of the in vitro translated protein
(see below).
In agreement with the previous results, all translation prod-
ucts were quantitatively degraded when a detergent was in-
cluded in the proteinase K digestion reaction. (Fig. 4A, lanes
3 and 6). Moreover, in order to distinguish whether the pu-
tative aspartic protease is an integral membrane protein em-
bedded in the lipid bilayer or a peripheral protein held in
association with the membrane by electrostatic interactions,
we challenged the in vitro translated, microsome associated
protein with a sodium carbonate solution at pH 11; under
these strong alkaline conditions, the three 35S-labeled bands
representing the ER-translocated, glycosylated protein were
coprecipitated with the microsomal membranes following ul-
tracentrifugation (Fig. 4B), suggesting that the protein under
scrutiny behaves in vitro like an integral membrane-spanning
protein.
Since addition of a single N-linked chain normally causes
an apparent increase in Mr of about 2 kDa and since the
primary sequence of the putative translation product contains
two potential N-glycosylation sites, we investigated the possi-
bility that the 58 and 60 kDa products could represent glyco-
sylated forms of the 56 kDa polypeptide. Treatment with
endoglycosidase H (Endo H), which removes N-linked, high
mannose oligosaccharide chains, resulted in the disappearance
of the 60 kDa polypeptide, indicating that it indeed represents
a glycosylated form of the 56 kDa polypeptide (Fig. 5A, lane
3). However, Endo H treatment did not apparently a¡ect the
58 kDa polypeptide. Since some glycan chains might be in-
accessible to the action of Endo H, we used two alternative
approaches to determine whether this latter polypeptide was
indeed glycosylated. N-linked glycosylation can be inhibited
in vitro by supplementing the translation reaction with an
acceptor tripeptide (acetyl)-Asn-Tyr-Thr-(amide) which com-
petes with the translated protein for the transfer of the oligo-
saccharide chain. As shown in Fig. 5B (lane 3), both the 58
and 60 kDa protein bands observed in the presence of micro-
somal membranes were not observed when the tripeptide was
included in the translation reaction, thus providing strong
evidence that both bands indeed represent di¡erent glyco-
forms of the in vitro synthesized polypeptide. The glycosylat-
ed nature of the two polypeptides was further con¢rmed by
including an inhibitor of ER glucosidase I in the translation
reaction. In the presence of this inhibitor, the removal of the
three glucose residues from the N-linked oligosaccharides
does not occur, resulting in a decreased mobility of the gly-
cosylated polypeptides. As expected, both bands were super-
shifted in the presence of such a inhibitor (Fig. 5C, lane 3),
thus providing de¢nitive evidence that both were glycosylated.
To con¢rm the in vitro evidence for DRAP behaving as a
transmembrane protein, we transfected HeLa cells with an
expression vector encoding DRAP tagged at its C-terminal
with a human c-myc epitope. Immuno£uorescence analysis
of Triton X permeabilized cells with a mouse conjugate anti-
body system directed against the c-myc epitope indicated that
at least some of the protein reaches the plasma membrane
whereas most is retained in an intracellular compartment,
possibly the Golgi (not shown).
4. Discussion
Down syndrome (DS) is the most frequent human aneu-
ploidy, occurring in 1 in 600 to 1 in 800 live births and is
Fig. 5. DRAP/BACE2 is a glycoprotein. A: DRAP/BACE2 was
translated in vitro as described before in the presence and absence
of microsomal membranes; an aliquot of the reaction was then
treated with Endo H as described in Section 2 before being analyzed
by SDS^PAGE. B: As an independent evidence of DRAP-1 glyco-
sylation, in vitro translation was performed in the presence of the
glycosylation inhibitor (acetyl)-Asn-Tyr-Thr-(amide) acceptor tripep-
tide. C: An independent in vitro translation reaction was also car-
ried out in the presence of the L-glucosidase inhibitor N-methyl-
deoxynojirimycin. Asterisks in panels A, B and C, lanes 2 indicate
the position of the 58 and 60 kDa bands observed in the presence
of microsomal membranes. Open circles in panel A, lane 3 and pan-
el C, lane 3 indicate the Endo H resistant form of DRAP/BACE2
and the two supershifted bands observed in the presence of N-meth-
yldeoxynojirimycin, respectively. The two short horizontal lines on
the left side of the picture represent the position of the protein mo-
lecular weight marker bands corresponding to 46 and 66 kDa.
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caused by the triplication of chromosome 21 [26]. The symp-
toms of this syndrome are considered to occur through dam-
age caused by overexpression of normal gene products en-
coded by genes on this chromosome. The elevated levels of
these proteins are thought to impair an unknown set of ge-
netic pathways which ensures normal cellular functioning [26].
A Down syndrome critical region (DSCR) on 21q has been
de¢ned on the basis of data obtained from patients with par-
tial triplication of chromosome 21 [26]. A consistent feature of
Down syndrome in middle aged patients is the deposition in
the brain of amyloid plaques resembling those observed in
Alzheimer disease [26]. L-secretases are important enzymes
in the generation of amyloid plaques, as they cleave APP to
release amyloidogenic peptides [27].
The discovery in chromosome 21 of a gene encoding a
membrane bound, putative aspartyl-protease highly homolo-
gous to L-secretase, is an intriguing ¢nding that could have
potential implications for the pathogenesis of one of the major
neurological ¢ndings of DS patients, namely the Alzheimer
disease-related manifestations. DRAP/BACE2 might repre-
sent a second type of L-secretase as indicated both by the
high level of homology to BACE-1 (Fig. 3) and by its trans-
membrane location (Fig. 5), a typical feature of BACE but
not of other aspartic proteases. Indeed it is known that
although ALAsp1 is the most prominent species formed
upon L-secretase cleavage, other amino terminal AL peptides,
like Val-3, Glu-11 and Ile-6, are also generated [28^31].
BACE-1 cleaves at Asp-1 and Glu-11 but not at other posi-
tions [10]. Interestingly, the NH2-terminal truncated AL forms
(in particular pyroglutamate 3^42) increase with age in
Down’s syndrome brain, and have a crucial role in promoting
AL aggregation in amyloid ¢brils [28^32].
Work is in progress to assess the cleavage speci¢city of
DRAP/BACE2 upon APP. If DRAP/ BACE2 should indeed
turn out to be a second L-secretase this would suggest the
intriguing hypothesis that increased dosage of both the genes
encoding the processing enzyme (DRAP/BACE2) and the
substrate (APP) could underlie the development of amyloid
plaques in Down patients.
During completion of this manuscript Saunders et al. and
Louis et al. [33,34] compared the sequence reported in this
paper (DRAP-1/BACE2 accession number AF050171 depos-
ited February 28, 1998) with BACE discussing their similar-
ities and named it BACE2.
The accession numbers of the human and mouse DRAP
cDNA sequences are AF050171 and AF051150, respectively.
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